- TG Therapeutics press release (NASDAQ:TGTX): Q2 GAAP EPS of $0.17 misses by $0.11.
- Revenue of $141.15M (+92.1% Y/Y) misses by $5.12M, including BRIUMVI U.S. net revenue of $138.8 million.
-
2025 Financial Guidance
- Raises BRIUMVI U.S. net product revenue target to $570 – $575 million for the full year 2025 (prior guidance of $560 million for full year 2025)
- Raises total global revenue target to approximately $585 million for the full year 2025 (prior guidance of $575 million for full year 2025)
2025 Remaining Pipeline Development Goals
- Commence patient enrollment into the Phase 3 pivotal program for subcutaneous BRIUMVI
- Continue enrollment into the Phase 3 pivotal program based on the streamlined dosing regimens evaluated in the ENHANCE trial, evaluating a single Day 1 600 mg IV dose of BRIUMVI
- Continue enrollment of participants into the ongoing clinical trial evaluating BRIUMVI in Myasthenia Gravis (MG)
- Continue enrollment of participants into the Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases, beginning with progressive forms of MS
- Present updated data at major medical conferences throughout the year
TG Therapeutics misses top-line and bottom-line estimates; raises FY25 outlook
